A recent study indicates that patients who come off new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle programs.
Published data in a major medical journal points out that while obese people often shed a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users using such drugs need to be aware of the potential of rapid rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment mass in about a year and a half.
Weighing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Scientists note that people who shed pounds through lifestyle changes alone generally see a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the way of the drugs accounts for the accelerated regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making overeating far more likely."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts contend that, due to the high risk of relapse, the treatment might need to be long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the chronic nature of excess weight," akin to managing diseases like diabetes.
Patient Accounts
Users who have come off the medication report a powerful resurgence of appetite.
"It was like something flipping and you become extremely hungry," described an individual.
The struggle is worsened if individuals have not developed lasting dietary or behavioural changes during treatment.
Significant Use
Survey data suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with interest being substantial.
- Use is greater among women than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and long-term success likely depends on combined lifestyle support.
